Jason Feinman, MD (@jjfein) 's Twitter Profile
Jason Feinman, MD

@jjfein

Incoming AHFTC Fellow @MountSinaiHeart. Current Chief Cardiology Fellow @SinaiCards. @MountSinaiNYC IM, @RWJMS and @BU_tweets alum

ID: 340441606

calendar_today22-07-2011 18:12:57

2,2K Tweet

482 Takipçi

281 Takip Edilen

CardioNerds (@cardionerds) 's Twitter Profile Photo

Get in the #HeartSuccess game! Check out the CardioNerds Heart Failure Guidelines Knowledge Hub featured on DocWire News for the latest updates and insights on #HF management! docwirenews.com/page/cardioner…

Get in the #HeartSuccess game! 

Check out the <a href="/CardioNerds/">CardioNerds</a> Heart Failure Guidelines Knowledge Hub featured on <a href="/mydocwire/">DocWire News</a> for the latest updates and insights on #HF management!   

docwirenews.com/page/cardioner…
C. Michael Gibson MD (@cmichaelgibson) 's Twitter Profile Photo

ARIES-HM3 Trial: In patients with HF receiving HM3 LVAD, VKA alone without aspirin results in no change in thrombotic outcomes, significantly less bleeding and less hospitalizations. Download slides for the ARIES-HM3 trial on excluding aspirin in LVAD HM3 presented at #AHA23

ARIES-HM3 Trial: In patients with HF receiving HM3 LVAD, VKA alone without aspirin results in no change in thrombotic outcomes, significantly less bleeding and less hospitalizations.

Download slides for the ARIES-HM3 trial on excluding aspirin in LVAD HM3 presented at #AHA23
Tina Reddy, MD, MPH (@tinakreddy) 's Twitter Profile Photo

👀@Cardionerds alert! From aortic disease to distal vessels, join experts dissect common presentations in a captivating case-based convo. Dr. Pollak guides us through diagnosis and management of PAD. 344. Beyond the Boards: Disease of the Peripheral Arteries with Dr. Amy Pollak

👀@Cardionerds alert! From aortic disease to distal vessels, join experts dissect common presentations in a captivating case-based convo. Dr. Pollak guides us through diagnosis and management of PAD.

344. Beyond the Boards: Disease of the Peripheral Arteries with Dr. Amy Pollak
Anu Lala-Trindade (@dranulala) 's Twitter Profile Photo

📣 calling all CardioNerds! How many of you have exposure to cardiac pathology review? ❤️🙏🏽 sessions w/ Barbara Sampson (previous Chief NY Med Examiner- 1st 💃🏽 in this role) reviewing complex 🫀biopsies & cases Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai Dr. Deepak L. Bhatt #FunctionNotFailure #ACCFIT

📣 calling all <a href="/CardioNerds/">CardioNerds</a>! How many of you have exposure to cardiac pathology review? ❤️🙏🏽 sessions w/ <a href="/BASampson/">Barbara Sampson</a> (previous Chief NY Med Examiner- 1st 💃🏽 in this role) reviewing complex 🫀biopsies &amp; cases <a href="/MountSinaiHeart/">Mount Sinai Fuster Heart Hospital</a> <a href="/IcahnMountSinai/">Icahn School of Medicine at Mount Sinai</a> <a href="/DLBHATTMD/">Dr. Deepak L. Bhatt</a> #FunctionNotFailure #ACCFIT
JACC Journals (@jaccjournals) 's Twitter Profile Photo

Join us now, Hall B-1 Main Tent, to celebrate #JACC Editor-in-Chief Dr. Valentin Fuster's contributions to cardiovascular medicine and science #ACC24 #CardioEd #cardiology

Join us now, Hall B-1 Main Tent, to celebrate #JACC Editor-in-Chief Dr. Valentin Fuster's contributions to cardiovascular medicine and science

#ACC24 #CardioEd #cardiology
Ivan Netuka (@netuka_ivan) 's Twitter Profile Photo

We are pleased to inform that our DOT-HM3 Trial results in partnership between IKEM and The Brigham Harvard just got online! Our results suggest a safety signal of Apixaban use with the HM3 up to a 6-months time point in stable LVAD patients. ahajournals.org/doi/abs/10.116…

We are pleased to inform that our DOT-HM3 Trial results in partnership between IKEM and The Brigham Harvard just got online! Our results suggest a safety signal of Apixaban use with the HM3 up to a 6-months time point in stable LVAD patients. ahajournals.org/doi/abs/10.116…
David Couto Mallón (@david_cm_) 's Twitter Profile Photo

Will this be the silver bullet to end with EMB as the gold-standard for post-HT monitoring? Results from the #SHORE registry show that the combination of GEP + dd-cfDNA is better associated with post-HT outcomes than EMB. Congrats all the authors for this amazing work #ishlt2024

Will this be the silver bullet to end with EMB as the gold-standard for post-HT monitoring? Results from the #SHORE registry show that the combination of GEP + dd-cfDNA is better associated with post-HT outcomes than EMB. Congrats all the authors for this amazing work #ishlt2024
Anu Lala-Trindade (@dranulala) 's Twitter Profile Photo

It’s not too late to apply for fellowship in #FunctionNotFailure Mount Sinai Fuster Heart Hospital! 🫀#4 Nationwide U.S. News & World Report 🫀World-renowned faculty Dr. Deepak L. Bhatt Gregg W. Stone MD Dr Roxana Mehran 🫀Personalized training pathways 🫀NYC 🌆 🫀Fellows who become colleagues! Join us for #AHFTC 2025-26!

It’s not too late to apply for fellowship in #FunctionNotFailure <a href="/MountSinaiHeart/">Mount Sinai Fuster Heart Hospital</a>!

🫀#4 Nationwide <a href="/usnews/">U.S. News & World Report</a> 
🫀World-renowned faculty <a href="/DLBHATTMD/">Dr. Deepak L. Bhatt</a> <a href="/GreggWStone/">Gregg W. Stone MD</a> <a href="/Drroxmehran/">Dr Roxana Mehran</a> 
🫀Personalized training pathways 
🫀NYC 🌆
🫀Fellows who become colleagues!

Join us for #AHFTC 2025-26!
CardioNerds (@cardionerds) 's Twitter Profile Photo

🎙️SGLT Inhibitors: Clinical Implementation of SGLT Inhibitors 🙏Kudos to Jason Feinman, MD, Gurleen Kaur, MD, & Richard Ferraro Alison L. Bailey, MD for this masterclass on SGLT inhibitor implementation 🤝#AHA24 registration is open! See you there: bit.ly/4gxzDwM, AHA Science

🎙️SGLT Inhibitors: Clinical Implementation of SGLT Inhibitors

🙏Kudos to <a href="/jjfein/">Jason Feinman, MD</a>, <a href="/Gurleen_Kaur96/">Gurleen Kaur, MD</a>, &amp; <a href="/RichardAFerraro/">Richard Ferraro</a> <a href="/a_l_bailey/">Alison L. Bailey, MD</a> for this masterclass on  SGLT inhibitor implementation 

🤝#AHA24 registration is open! 

See you there: bit.ly/4gxzDwM, <a href="/AHAScience/">AHA Science</a>